Affimed(US:AFMD)2024-06-12 12:19Clinical Program Updates - Acimtamig (AFM13) + AlloNK® (AB-101) in r/r HL showed an ORR of 85.7% (6/7) including 4 CRs[8] - AFM24 + Tecentriq® (atezolizumab) in r/r EGFR+ NSCLC showed 4 confirmed responses and PFS of 5.9 months in EGFRwt patients[8] - AFM28 monotherapy in r/r AML at dose level 6 (300mg) reported a CR/CRi rate of 33% (2/6)[8] LuminICE-203 (Acimtamig + AlloNK) Trial - In the LuminICE-203 study, 7 patients data showed ORR of 85.7% and CRR of 57%[19] - The LuminICE-203 study enrolled patients with a median of 4 prior lines of therapy, with 100% having received prior brentuximab vedotin and checkpoint inhibitor treatment[21] AFM24-102 (AFM24 + Atezolizumab) Trial - In EGFRwt NSCLC patients, median PFS was 5.9 months[28] - In EGFRwt NSCLC patients, tumor shrinkage was observed in 8 (47%) patients (n=17)[26] - In EGFRmut NSCLC patients, 4 confirmed responses were observed (n=13)[31] AFM28-101 Trial - At dose level 6 (300 mg), the CR/CRi rate was 33% (2/6)[36] - In dose level 5 (250mg), 1 patient is in ongoing CR for 5 months/cycles[36] Financial Status - As of March 31, 2024, total cash, cash equivalents, and investments were €48.5 million[42] - Net cash used in operating activities for the quarter ended March 31, 2024, was €(23.8) million[43] - The company is funded into H2 2025 to drive clinical development[8]